CLINICAL TRIALS PROFILE FOR AMLODIPINE BESYLATE
✉ Email this page to a colleague
All Clinical Trials for AMLODIPINE BESYLATE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00136851 ↗ | Study Comparing the Efficacy of Amlodipine Besylate/Benazepril Versus Amlodipine in the Treatment of Severe Hypertension | Completed | Novartis Pharmaceuticals | Phase 4 | 2004-12-01 | This trial is designed to study the efficacy of an amlodipine besylate/benazepril treatment regimen versus an amlodipine treatment regimen in the treatment of severe hypertension. |
| NCT00289406 ↗ | Efficacy and Safety Study of S-Amlodipine Gentisate Compared to Amlodipine Besylate to Treat Mild-to-Moderate Hypertension | Completed | SK Chemicals Co., Ltd. | Phase 3 | 2006-01-01 | The goal of this study is to compare the antihypertensive effect and tolerability of S-amlodipine gentisate with those of amlodipine besylate in patients with mild to moderate hypertension. |
| NCT00289406 ↗ | Efficacy and Safety Study of S-Amlodipine Gentisate Compared to Amlodipine Besylate to Treat Mild-to-Moderate Hypertension | Completed | SK Chemicals Co.,Ltd. | Phase 3 | 2006-01-01 | The goal of this study is to compare the antihypertensive effect and tolerability of S-amlodipine gentisate with those of amlodipine besylate in patients with mild to moderate hypertension. |
| NCT00311155 ↗ | Olmesartan and an add-on Treatment in Patients With Mild to Moderate Hypertension | Completed | Sankyo Pharma Gmbh | Phase 4 | 2006-03-01 | This study is to assess the safety and efficacy of an add-on treatment algorithm with olmesartan, hydrochlorothiazide and amlodipine in patients with mild to moderate hypertension. |
| NCT00412113 ↗ | A Multi-Risk Factor Strategy vs a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensives at Extra Risk | Completed | Pfizer | Phase 4 | 2007-01-01 | The purpose of this study is to investigate whether an aggressive multi-risk factor management strategy (Caduet plus therapeutic lifestyle changes (TLC) regimen) will result in greater percentage of patients achieving blood pressure and low density lipoprotein cholesterol (LDL-C) goals compared with a Joint National Committee 7/ National Cholesterol Education Program Adult Treatment Panel III (JNC 7/NCEP ATP III) guideline-based approach (Norvasc plus TLC regimen) after 6 weeks of treatment in primary prevention subjects with hypertension and additional risk factors, including dyslipidemia. |
| NCT00412113 ↗ | A Multi-Risk Factor Strategy vs a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensives at Extra Risk | Completed | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Phase 4 | 2007-01-01 | The purpose of this study is to investigate whether an aggressive multi-risk factor management strategy (Caduet plus therapeutic lifestyle changes (TLC) regimen) will result in greater percentage of patients achieving blood pressure and low density lipoprotein cholesterol (LDL-C) goals compared with a Joint National Committee 7/ National Cholesterol Education Program Adult Treatment Panel III (JNC 7/NCEP ATP III) guideline-based approach (Norvasc plus TLC regimen) after 6 weeks of treatment in primary prevention subjects with hypertension and additional risk factors, including dyslipidemia. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for AMLODIPINE BESYLATE
Condition Name
Clinical Trial Locations for AMLODIPINE BESYLATE
Trials by Country
Clinical Trial Progress for AMLODIPINE BESYLATE
Clinical Trial Phase
Clinical Trial Sponsors for AMLODIPINE BESYLATE
Sponsor Name
